Finance

Cancer vaccine maker reports loss of $0.54 per share

Published in Vaccine Weekly, November 10th, 2004

Cell Genesys, Inc., (CEGE) announced select preliminary financial results for the third quarter ended September 30, 2004.

The company expects to report revenues of approximately $3.2 million and a net loss of approximately $24.0 million, or $0.54 per share, for the quarter ended September 30, 2004.

Cell Genesys also expects to report that it ended the quarter with approximately $152.6 million in cash, cash equivalents and short-term investments, including restricted cash and investments, and in addition held approximately 6.6 million shares of its former subsidiary, Abgenix, Inc.

Cell Genesys is focused on the development and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-11-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry